Articles written by Vandana Singh - Benzinga

FTC Delays Drug Middlemen Case While Talks Move Forward

FTC Delays Drug Middlemen Case While Talks Move Forward

The FTC paused its case against major pharmacy benefit managers for 14 days to review a possible settlement, delaying hearings and deadlines.

Abbott's India Unit Under Scrutiny Due To Phensedyl Cough Syrup Supply Chain

Abbott's India Unit Under Scrutiny Due To Phensedyl Cough Syrup Supply Chain

Indian authorities probe Abbott Healthcare's Phensedyl supply chain as documents flag excess sales and alleged diversion.

Pfizer CEO Calls RFK's Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research

Pfizer CEO Calls RFK's Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges stronger global competitiveness.

CVRx Kicks Off One Of The Largest Heart Device Trials In History

CVRx Kicks Off One Of The Largest Heart Device Trials In History

CVRx, Inc. initiates landmark BENEFIT-HF trial with FDA-approved Barostim device, aiming to expand heart failure patient population.

FDA Issues Alert For Integra Wound Care Products Over Infection Fears

FDA Issues Alert For Integra Wound Care Products Over Infection Fears

FDA warns of high-risk device issue with wound and burn care products by Integra LifeSciences, citing infection risks.

ClearPoint Neuro Gets EU Green Light For Updated Brain Surgery Software

ClearPoint Neuro Gets EU Green Light For Updated Brain Surgery Software

ClearPoint Neuro receives EU certification for its navigation software, expanding brain surgery access as the company reports strong revenue growth and outlines higher sales expectations for 2026.

Novartis Positions US Strategy As Defense Against Rising Trade Levies

Novartis Positions US Strategy As Defense Against Rising Trade Levies

Novartis CEO says US manufacturing investments and a federal agreement could limit tariff exposure as proposed Trump levies target Europe.

Why Your Pneumonia Shot Is About To Get A Massive Upgrade

Why Your Pneumonia Shot Is About To Get A Massive Upgrade

Vaxcyte shares rise after starting Phase 3 trials for its VAX-31 pneumonia vaccine, expanding studies in adults and infants while planning major U.S. manufacturing investments.

Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It

Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It

Structure Therapeutics CEO discusses oral GLP-1 strategy, Phase 3 plans, and why pills and combination therapies may reshape obesity treatment.

Sanofi Plans Regulatory Filings For Dupixent's Successor Despite Mixed Data From Pivotal Studies

Sanofi Plans Regulatory Filings For Dupixent's Successor Despite Mixed Data From Pivotal Studies

Sanofi released late-stage study results for amlitelimab, a new eczema drug showing strong skin improvement and good safety, with more trial data expected in 2026.

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Janux Therapeutics signs a global licensing deal with Bristol Myers Squibb worth up to $800 million.

FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer

FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer

FDA approves Guardant Health's blood test to help identify metastatic colorectal cancer patients eligible for targeted treatment.

Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half

Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half

Hoth Therapeutics reported interim trial results showing all patients improved by Week 6, with reduced disease severity, fewer side effects, and early lasting benefits in cancer patients on EGFR therapy.

Axogen Prices Upsized $124 Million Stock Offering

Axogen Prices Upsized $124 Million Stock Offering

Axogen stock fell Thursday with a session volume of 1.92 million, priced its upsized underwritten public offering at $31.00 per share.

Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps

Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps

Corcept stock rises after a Phase 3 ovarian cancer trial showed longer survival and lower death risk, even as relacorilant faces an FDA setback in another use.

Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints

Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast higher full-year profits and steady sales growth.

UnitedHealth CEO Says Hospitals, Drug Prices Drive US Health Care Costs, Pledges ACA Rebates

UnitedHealth CEO Says Hospitals, Drug Prices Drive US Health Care Costs, Pledges ACA Rebates

UnitedHealth CEO tells Congress that hospital prices, drug costs, and consolidation—not insurers—are driving U.S. health care spending higher.

Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure

Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure

Telix Pharmaceuticals meets its FY25 revenue target with strong Q4 growth, expanded U.S. launches and ongoing trials.

Apellis Valuation Ignores Empaveli Potential, Says Analyst

Apellis Valuation Ignores Empaveli Potential, Says Analyst

BofA upgraded Apellis to Buy, citing strong early Empaveli uptake, FDA approval in rare kidney disease, and long-term sales upside.

Nano-Cap Brand Engagement Network Stock Rallies As Africa AI Deal Fuels Investor Buzz

Brand Engagement Network shares rise on heavy volume after securing a $2.05 million AI licensing partnership in Africa, boosting momentum as investors react to the strategic deal.